& human disease conference
October 19-23, 2021
All major physiological phenomena are regulated by protein phosphorylation which is catalysed by protein kinases. Many diseases are associated with abnormal phosphorylation. Consequently, the last four decades have seen considerable efforts in the study of function and regulation of protein kinases in essentially all aspects of biology. In parallel, pharmacological inhibitors of kinases have become a major R&D area for the pharmaceutical industry in its search for new therapies. As of early 2020, 49 kinase inhibitors have reached the pharmaceutical market.
DYRKs (‘dual specificity, tyrosine phosphorylation regulated kinase 1’) (DYRK1A, 1B, 2, 3, 4) play key roles in mRNA splicing, chromatin transcription, DNA damage repair, cell survival, cell cycle, differentiation, endocytosis, neuronal development and functions, synaptic plasticity, folate and methionine metabolism. Inhibition of DYRKs may find applications in Down syndrome, Alzheimer’s disease and tauopathies, Parkinson’s disease, CDKL5 Deficiency Disorder diabetes, osteoarthritis, viral infections and various cancers. The closely related CLKs (‘cdc2-like kinases) (CLK1, 2, 3, 4) also play essential functions in Alzheimer’s disease and tauopathies, alternative splicing, various viral infections, cancers, body temperature sensing. DYRK and CLK orthologs are found in plants, yeast and unicellular parasites.
The conference will focus on DYRK1A and related kinases, including structural, regulatory and functional aspects, substrates and interactors, functions at cell and organism levels as well as development and potential therapeutic use of selective pharmacological inhibitors.
Palais du Grand Large, St Malo, Bretagne, France
Department of Anatomy
& Developmental Biology,
Graduate School of Medicine,
Kyoto University, Kyoto, Japan
Peter P. DE DEYN
Department of Neurology,
General Hospital Middelheim and Institute Born-Bunge University of Antwerp,
Mariona ARBONES, Barcelona, Spain
Control of neuron numbers by DYRK1A: lessons from mouse models
Walter BECKER, Aachen, Germany
DYRK1B – a cancer drug target?
Thierry BESSON, Rouen, France
Novel DYRKs/CLKs inhibitors
Mara DIERSSEN, Barcelona, Spain
Clinical trials with EGCG, PERSEUS trial
Peter DE DEYN, Antwerpen, Belgium
Down syndrome, Alzheimer’s disease & DYRK1A
Susana DE LA LUNA, Barcelona, Spain
DYRK1A & DNA damage
Masatoshi HAGIWARA, Kyoto, Japan
Development of inhibitors of CLK1 and DYRK1A, and their clinical applications
Yann HERAULT, Strasbourg, France
The role of DYRK1A dosage in Down syndrome deficits
Florian HEYD, Berlin, Germany
CLK in body temperature cycles
Nathalie JANEL, Paris, France
DYRK1A interactants, a link between Down's syndrome and Alzheimer’s disease
Stefan KNAPP, Frankfurt, Germany
Selective targeting of kinases regulation RNA splicing
Akiko KOBAYASHI, Kyoto, Japan
Neuroprotection through suppression of inflammation by DYRK inhibitors
Conrad KUNICK, Braunschweig, Germany
New DYRK1B inhibitors
Laurent MEIJER, Roscoff, France
Leucettinibs, a second-generation family of DYRKs/CLKs inhibitors: from natural products to clinical
Lenka MUNOZ, Sydney, Australia
Phosphoproteomic screen in cells upon DYRK1A inhibition: identification of new DYRK1A down-stream
William M. OLD, Boulder & Aurora, USA
Revealing new functions of DYRK1A through interactome and substrate profiling
Sang Ki PARK, Pohang, Korea
Sequential phosphorylation of NDEL1 by the DYRK2-GSK3β complex is critical for neuronal
Lucas PELKMANS, Zurich, Switzerland
Kinase-controlled phase transition of membrane-less organelles in mitosis
Amélie PITON, Illkirch, France
DYRK1A, a gene frequently mutated in intellectual disability
Randall J. ROPER, Indianapolis, USA
DYRK1A and skeletal deficits associated with Down syndrome
Andrew F. STEWART, New York, USA
DYRK1A inhibitors for beta cell proliferation to treat diabetes
Invited speakers (tentative titles)
The final program will be available in September 2021.
Organization: Arial 11, 1 page maximum, title (bold), authors (underline presenting author), address, e-mail contact, abstract, 1-3 compact references, (funding). Save under ‘yourname.doc’ or ‘yourname.docx’.
Submit abstract as an attached Word document, through the Conference e-mail address (firstname.lastname@example.org), with your name as ‘subject’.
Abstract submission deadline: August 31, 2021.
Instructions for speakers
There will be no poster sessions. We will try to have as many people as possible, especially students and post-docs, presenting their results. Besides invited speakers, submitted abstracts will be selected for long (15 min) or short (5 min) oral presentations (+ 5 min discussion).
Call for authors
We plan to put together an open-access e-book collating articles on the conference topic. It will be published by Frontiers in Neurology (www.frontiersin.org). Contribution to this e-book will be open to everyone, whether attending or not to the conference. The plan is to have the final e-book ready by the opening of the conference. Please consider this opportunity. More information will be sent to the DYRKs/CLKs community in the coming months.
Travel grants for young researchers
The « Fondation Vaincre Alzheimer » is open to receive travel grant applications from young researchers. Do not hesitate to submit your application at: https://www.vaincrealzheimer.org/espace-chercheur-bourse-voyage/
Getting to Saint-Malo
The easiest: Fast train (TGV) from Paris-Montparnasse train station.
Please consult our information for international access here.
Saint-Malo & Brittany
Fill in the registration form and send it to .
Very early bird registration deadline: June 30, 2021.
Early bird registration deadline: August 6, 2021.
Late registration: August 6, 2021 up to September 15, 2021.
Start of the conference: October 19, 2021 at 17:00.
End of the conference: October 23, 2021 at 12:00.
Registration comprises access to all conferences, program, coffee/tea breaks and lunches.
Very early bird registration deadline:
Industry: 600 € Academy: 500 € PhD Students*: 300 €.
Early bird registration deadline:
Industry: 800 € Academy: 600 € PhD Students*: 400 €.
Industry: 1000 € Academy: 700 €. PhD Students*: 500 €.
* Photocopy of student card required
Nota Bene. In case a pandemic crisis prevents you to join the conference, your registration will be fully reimbursed (up to September 19).
Please consult our list of accommodation here.